Antiplatelet Conversion - Switching Between P2Y12 Inhibitors
Oral P2Y12 inhibitors vary in potency and pharmacokinetic and dynamic parameters.
Switching P2Y12 inhibitors during hospitalization for acute coronary syndrome patients (ACS) has been reported at rates ranging from 9 to 24%.
Drug interactions between P2Y12 inhibitors can lead to inadequate platelet inhibition and risk of thrombotic complications.
Inappropriate overlap of P2Y12 inhibitors can lead to excessive platelet inhibition and risk of bleeding complications.
• Switching Between Intravenous (Cangrelor) and Oral P2Y12 Inhibitors
• Switching Among Oral P2Y12 Inhibitors
- Escalation in Potency: Clopidogrel to Prasugrel, Clopidogrel to Ticagrelor
- De-escalation in Potency: Prasugrel to Clopidogrel, Ticagrelor to Clopidogrel
- Change Between High Potency: Prasugrel to Ticagrelor, Ticagrelor to Prasugrel
#P2Y12 #Inhibitor #switching #conversion #Clopidogrel #plavix #antiplatelet #ticagrelor #prasugrel #pharmacology #Cangrelor
